CAMBRIDGE MA — In October 2013, GigaGen and Novartis entered into a research collaboration to develop GigaGen’s Synthetic ImmunologyTM technology for applications in human therapeutic antibody discovery. We are thrilled to collaborate with Novartis, which is consistently admired as an innovation leader in biological therapeutics. The deal is part of Novartis’ broader efforts to work with innovative early stage companies through a combination of equity investment and research collaboration.